Compare · JNJ vs PGEN
JNJ vs PGEN
Side-by-side comparison of Johnson & Johnson (JNJ) and Precigen Inc. (PGEN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JNJ and PGEN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $658.24B, about 252.5x PGEN ($2.61B).
- Over the past year, JNJ is up 54.8% and PGEN is up 71.5% - PGEN leads by 16.7 points.
- PGEN has been more active in the news (12 items in the past 4 weeks vs 11 for JNJ).
- JNJ has more recent analyst coverage (25 ratings vs 4 for PGEN).
- Company
- Johnson & Johnson
- Precigen Inc.
- Price
- $273.23+0.07%
- $7.28+1.61%
- Market cap
- $658.24B
- $2.61B
- 1M return
- +2.75%
- +34.32%
- 1Y return
- +54.76%
- +71.50%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 11
- 12
- Recent ratings
- 25
- 4
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Precigen Inc.
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch inducible gene switch that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Ares Trading S.A.; Oragenics, Inc.; Intrexon T1D Partners, LLC; Intrexon Energy Partners, LLC; Intrexon Energy Partners II, LLC; Fibrocell Science, Inc.; OvaXon, LLC; S & I Ophthalmic, LLC; Harvest start-up entities; and Surterra Holdings, Inc. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
Latest JNJ
- FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients
- EVP, WWC. Innovative Medicine Taubert Jennifer L exercised 15,000 shares at a strike of $115.67 and sold $3,950,400 worth of shares (15,000 units at $263.36) (SEC Form 4)
- CEO and Chairman of the Board Duato Joaquin exercised 123,291 shares at a strike of $115.67 and sold $32,199,927 worth of shares (123,291 units at $261.17) (SEC Form 4)
- Johnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
- CEO and Chairman of the Board Duato Joaquin sold $12,515,010 worth of shares (48,480 units at $258.15), decreasing direct ownership by 15% to 275,967 units (SEC Form 4)
- EVP, Chief Legal Officer Forminard Elizabeth exercised 9,344 shares at a strike of $131.94 and sold $4,090,960 worth of shares (15,918 units at $257.00), decreasing direct ownership by 28% to 16,994 units (SEC Form 4)
- SEC Form 13F-HR filed by Johnson & Johnson
- A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout
- Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conference
- Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One
Latest PGEN
- Director Agee Nancy H bought $24,662 worth of shares (3,411 units at $7.23), increasing direct ownership by 1% to 309,187 units (SEC Form 4)
- Chief Legal Officer Lehr Donald P. converted options into 5,208 shares and covered exercise/tax liability with 2,488 shares, increasing direct ownership by 0.36% to 758,181 units (SEC Form 4) (tax liability)
- Chief Financial Officer Thomasian Harry Jr. converted options into 7,291 shares and covered exercise/tax liability with 3,577 shares, increasing direct ownership by 1% to 258,249 units (SEC Form 4) (withholding obligation)
- Chief Operating Officer Shah Rutul R exercised 57,500 shares at a strike of $2.03, sold $375,000 worth of shares (50,000 units at $7.50) as part of a pre-agreed trading plan and covered exercise/tax liability with 3,647 shares, increasing direct ownership by 0.83% to 468,865 units (SEC Form 4) (withholding tax)
- Chief Commercial Officer Tennant Phil exercised 84,374 shares at a strike of $1.51, covered exercise/tax liability with 2,585 shares and sold $593,745 worth of shares (79,166 units at $7.50) as part of a pre-agreed trading plan, increasing direct ownership by 2% to 141,992 units (SEC Form 4) to satisfy withholding tax
- President and CEO Sabzevari Helen converted options into 20,833 shares and covered exercise/tax liability with 10,184 shares, increasing direct ownership by 0.28% to 3,779,521 units (SEC Form 4) to satisfy withholding obligation
- Precigen's Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven Cancers
- Chief Operating Officer Shah Rutul R sold $224,590 worth of shares (32,739 units at $6.86) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 465,012 units (SEC Form 4)
- SEC Form 10-Q filed by Precigen Inc.
- Precigen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits